美股異動 | 阿斯麥(ASML.US)盤前漲6.42% Q3業績超預期 預計新規對明年出貨的直接影響有限
格隆匯10月19日丨阿斯麥(ASML.US)盤前漲6.42%,報424.59美元。該公司今日公佈業績,第三季度淨營收同比增長10%至58億歐元,超預期的53.9億歐元;淨利潤同比下降2.24%至17.01億歐元,但超預期的14.2億歐元。公司預計第四季度淨營收61-66億歐元,市場預期為61.3億歐元;預計全年淨營收211億歐元,毛利率接近50%。公司CEO Peter Wennink表示,市場對阿斯麥的產品需求依然強勁,三季度預定量達創紀錄的89億歐元;公司初步評估顯示,美國出口管理條例新規對公司的2023年整體出貨計劃的直接影響有限。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.